Explorer les evidences

4 %The prevalence of the 233F/V substitution in protease sequences was 4% (2/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

33 patientsThe study included 33 insulin-resistant HIV-infected patients.

Camerouninsulin resistance · VIH/sidapublié 2011Nutrientseurope_pmcdocument de 5 observationsDOI 10.3390/nu3070712

52 %The incidence of drug-induced hepatotoxicity (DIH) was 52% among HIV patients in Cameroon.

Cameroundrug-induced hepatotoxicity · VIH/sidaobservé 2018-2019publié 2024BMC infectious diseaseseurope_pmcdocument de 4 observations

7 %Among adults tested for HIV during the campaign, 588 (7%) tested HIV-positive.

CamerounVIH/sidapublié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

22 %22% of the studied HIV viruses had nef and gag genes from viruses belonging to different clades.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

23,6 %Among 458 patients who initiated antiretroviral therapy in rural district hospitals in Cameroon between 2006 and 2008, 108 (23.6%) had a CD4 count above 350 cells/mm³.

CamerounVIH/sidaobservé 2006-2008publié 2010Tropical medicine & international health : TM & IHeurope_pmcdocument de 7 observations

8 %The prevalence of antiretroviral drug resistance among patients on first-line antiretroviral treatment in rural Cameroon was 8.0% in the 6- to 12-month group and 27.1% in the >72-month group.

CamerounVIH/sidaobservé 2013-2014publié 2016Open Forum Infectious Diseaseseurope_pmcdocument de 3 observations

16 %The prevalence of the 16E substitution in protease sequences was 16% (9/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

3,5 %At endpoint, 3.5% of 141 HIV-infected adult patients transferred.

CamerounVIH/sidaobservé 2009-2011publié 2013PLoS ONEOpenAlexdocument de 8 observationsDOI 10.1371/journal.pone.0072680

8,2 %Prevalence was 8.2% across prior days of the health fair.

CamerounVIH/sidapublié 2012Journal of the International AIDS Societyeurope_pmcdocument de 39 observations

4 %The prevalence of the 399D substitution in reverse transcriptase sequences was 4% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

-0,34 SMDAmong HIV+ individuals, antiretroviral therapy use was associated with lower glycated hemoglobin with a standardized mean difference of -0.34.

Camerounglycated hemoglobin · VIH/sidapublié 2013International journal of epidemiologyeurope_pmcdocument de 10 observationsDOI 10.1093/ije/dyt198

93 %The prevalence of the 69K/R substitution in protease sequences was 93% (53/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

100 %The prevalence of the 36I/L substitution in protease sequences was 100% (57/57) among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

12 %The prevalence of unsuppressed viral load among patients on first-line antiretroviral treatment in rural Cameroon was 12.0% in the 6- to 12-month group and 31.3% in the >72-month group.

CamerounVIH/sidaobservé 2013-2014publié 2016Open Forum Infectious Diseaseseurope_pmcdocument de 3 observations

4,8 %In rural areas of Cameroon with more recently implemented ART programs, the prevalence of WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among ART-naive individuals was 4.8% in 2006–2007.

CamerounVIH/sidaobservé 2006–2007publié 2011AIDS (London, England)europe_pmcdocument de 5 observationsDOI 10.1097/qad.0b013e32834bbbe9

There was a significant trend towards a positive change in body mass index with increasing duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublié 2013Diabetes & metabolismeurope_pmcdocument de 12 observations

HIV-1 subtype A represents 60–90% of HIV subtypes circulating in West and Central Africa.

CamerounVIH/sidaobservé Preliminary datapublié 1998PubMedOpenAlexdocument de 10 observations

12,3 %In Yaoundé, the capital city of Cameroon, the prevalence of WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among ART-naive individuals was 12.3% in 2007.

CamerounVIH/sidaobservé 2007publié 2011AIDS (London, England)europe_pmcdocument de 5 observationsDOI 10.1097/qad.0b013e32834bbbe9

1,9 %In Yaoundé, the capital city of Cameroon, the prevalence of WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among ART-naive individuals was 1.9% in 2001.

CamerounVIH/sidaobservé 2001publié 2011AIDS (London, England)europe_pmcdocument de 5 observationsDOI 10.1097/qad.0b013e32834bbbe9

9 %Phylogenetic analysis of the gp41 region of 123 HIV-1-seropositive specimens from Cameroon showed that 11 (9%) were subtype G.

CamerounVIH/sidapublié 2000AIDS Research and Human RetrovirusesOpenAlexdocument de 7 observations

The prevalence of non-subtype-B HIV-1 strains continues to increase in industrialized countries.

CamerounVIH/sidapublié 2000Journal of Clinical MicrobiologyOpenAlexdocument de 19 observations

5 %Three nef sequences (5%) were neither obviously recombinant nor easily classifiable into any of the known HIV-1M clades.

CamerounVIH/sidapublié 2013Virology JournalOpenAlexdocument de 7 observationsDOI 10.1186/1743-422x-10-29

7 %The prevalence of the 39A substitution in reverse transcriptase sequences was 7% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublié 2011AIDS Research and Human RetrovirusesOpenAlexdocument de 24 observations

1,26 hazard_ratioHIV-positive patients over 39 years old had a hazard ratio of 1.26 for early antiretroviral treatment initiation.

CamerounVIH/sidaobservé 2014publié 2020Health Policy and PlanningOpenAlexdocument de 6 observationsDOI 10.1093/heapol/czaa153